DOCSLIB.ORG

Tenncare Attestation List September 1, 2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Tenncare Attestation List September 1, 2021 TennCare Attestation List September 1, 2021 Medications on this list can be approved for patients currently at their monthly prescription limit (greater than 5 prescriptions or greater than 2 brand medications), who are at a high risk for adverse health consequences and could be hospitalized, institutionalized, or die within the next 90 days without the requested drug(s). This list is independent of the preferred drug list (PDL) and other criteria. All drugs on this list are still subject to existing TennCare edits, including non- preferred status on the PDL, clinical criteria, step therapy criteria, and quantity limits.* ANTI-INFECTIVES Aminoglycosides • amikacin (Amikin, Arikayce) • neomycin (Neo-Fradin) • gentamicin (Garamycin) • paromomycin • kanamycin • streptomycin Cephalosporins, 1st Generation • cefadroxil (Duricef) • cephalexin (Keflex) • cefazolin (Ancef) Cephalosporins, 2nd Generation • cefaclor (Ceclor) • cefprozil (Cefzil) • cefoxitin (Mefoxin) • cefuroxime (Ceftin, Zinacef) Cephalosporins, 3rd Generation • cefdinir • ceftazidime (Fortaz, Tazicef) • cefditoren (Spectracef) • ceftibuten (Cedax) • cefixime (Suprax) • ceftizoxime (Cefizox) • cefotaxime (Claforan) • ceftriaxone (Rocephin) • cefpodoxime (Vantin) Cephalosporins, 4th Generation • cefepime (Maxipime) Ketolides • telithromycin (Ketek) Lincosamides • clindamycin (Cleocin) • lincomycin (Lincocin) Macrolides • azithromycin (Zithromax) • erythromycin (E.E.S., Eryc, Ery-Tab, EryPed) • clarithromycin (Biaxin, Biaxin XL) • erythromycin/sulfisoxazole (Eryzole, Pediazole) • fidaxomicin (Dificid) Nitrofurans • nitrofurantoin (Furadantin, Macrodantin, Macrobid) Nitroimidazoles • metronidazole HCl (Flagyl) • tinidazole (Tindamax) Oxazolidinones • linezolid (Zyvox) • tedizolid (Sivextro) ANTI-INFECTIVES Penicillins • amoxicillin/potassium clavulanate (Augmentin, Augmentin XR) • oxacillin • amoxicillin (Amoxil, Moxatag) • penicillin G (Bicillin C-R, Bicillin L-A, Permapen) • ampicillin • penicillin V potassium (Veetids) • ampicillin/sulbactam (Unasyn) • piperacillin • dicloxacillin • piperacillin/tazobactam (Zosyn) • nafcillin • ticarcillin/potassium clavulanate (Timentin) Quinolones • ciprofloxacin (Cipro, Cipro XR, Proquin XR) • moxifloxacin • delafloxacin (Baxdela) • norfloxacin (Noroxin) • gemifloxacin (Factive) • ofloxacin (Floxin) • levofloxacin (Levaquin) Sulfonamides • sulfadiazine • sulfasalazine (Azulfidine) • sulfamethoxazole/trimethoprim (Bactrim, Septra) • trimethoprim Tetracyclines • demeclocycline • minocycline (Arestin, Dynacin, Minocin, Myrac) • doxycycline (Adoxa, Atridox, Dory MPC, Doryx, Monodox, • tetracycline (Sumycin) Oracea, Oraxyl, Periostat, Vibramycin) Vancomycin and Derivatives • vancomycin (Firvanq, Vancocin) Miscellaneous Antibiotics • fosfomycin (Monurol) • methenamine (Hiprex, Urex) • Lefamulin (Xenleta) Antifungals • amphotericin B (Abelcet, AmBisome, Amphocin, Amphotec) • itraconazole (Sporanox, Tolsura) • anidulafungin (Cancidas) • ketoconazole • caspofungin (Eraxis) • micafungin (Mycamine) • fluconazole (Diflucan) • miconazole (Monistat) • flucytosine (Ancobon) • posaconazole (Noxafil) • griseofulvin (Fulvicin U/F, Gris-PEG, Grifulvin V) • voriconazole (Vfend) • isavuconazonium (Cresemba) Antiparasitics • albendazole (Albenza) • nitazoxanide (Alinia) • artemether/lumefantrine (Coartem) • paromomycin • atovaquone/proguanil (Malarone) • pentamidine (NebuPent, Pentam 300) • atovaquone (Mepron) • praziquantel (Biltricide) • chloroquine (Aralen) • primaquine • dapsone • pyrantel (Pin-X, Reese Pinworm) • iodoquinol (Yodoxin) • pyrimethamine (Daraprim) • ivermectin (Stromectol) • quinine (Qualaquin) • mebendazole (Emverm, Vermox) • tafenoquine (Krintafel) • mefloquine Antivirals • acyclovir (Zovirax) • penciclovir (Denavir) • baloxavir (Xofluza) • valacyclovir (Valtrex) • famciclovir (Famvir) • zanamivir (Relenza) • oseltamivir (Tamiflu) • ledipasvir/sofosbuvir (Harvoni and Harvoni Pak) • dolutegravir (Tivicay and Tivicacy PD) • sofosbuvir (Sovaldi and Sovaldi Pak) Effective Date: 9/1/2021 TennCare Attestation List | Page 2 CARDIOVASCULAR Antianginal Agents, Miscellaneous • ranolazine (Ranexa) Antiarrhythmics • adenosine (Adenocard) • ibutilide (Corvert) • amiodarone (Cordarone, Pacerone) • lidocaine (Xylocaine) • bretylium • mexiletine (Mexitil) • disopyramide IR/SA (Norpace/Norpace CR) • procainamide • dofetilide (Tikosyn) • propafenone (Rythmol/Rythmol SR) • dronedarone (Multaq) • quinidine gluconate • flecainide (Tambocor) • quinidine sulfate (Quinidex) Anticoagulants • apixaban (Eliquis) • fondaparinux (Arixtra) • dalteparin (Fragmin) • heparin (Heparin) • dabigatran etexilate (Pradaxa) • tinzaparin (Innohep) • edoxaban (Savaysa) • warfarin (Coumadin, Jantoven) • enoxaparin (Lovenox) Antifibrinolytics • aminocaproic acid (Amicar) • avatrombopag (Doptelet) • aprotinin (Trasylol) • tranexamic acid (Cyklokapron, Lysteda) Cardiac Glycosides • digoxin (Lanoxin) Calcium Channel Blockers • amlodipine (Katerzia) • nimodipine (Nymalize/Nymalize ER) Hypotensives, Angiotensin Receptor Blockers • azilsartan (Edarbi) • eprosartan/HCTZ (Teveten HCT) • azilsartan/chlorthalidone (Edarbyclor) Hypotensives, Direct Renin Inhibitors • aliskiren (Tekturna) • aliskiren/HCTZ (Tekturna HCT) Hypotensives, Sympatholytics • clonidine (Catapres, Catapres TTS) • methyldopa/HCTZ • guanfacine (Tenex) • methyldopate • mecamylamine (Vecamyl) • reserpine • methyldopa (Aldomet) Hypotensives, Vasodilators • diazoxide (Hyperstat I.V.) • hydralazine HCl (Apresoline) • fenoldopam mesylate (Corlopam) • minoxidil (Minoxidil) Miscellaneous, Cardiovascular • ecallantide (Kalbitor) • ivabradine (Corlanor) • icatibant (Firazyr) Oral Thrombopoietic Agonists • eltrombopag (Promacta) • lusutrombopag (Mulpleta) • fostamatinib (Tavalisse) Pheochromocytoma Agents • metyrosine (Demser) Platelet Aggregation Inhibitors/Intermittent Claudication • abciximab (ReoPro) • omeprazole/aspirin (Yosprala) • anagrelide (Agrylin) • pentoxifylline (Trental) • aspirin (Durlaza) • prasugrel (Effient) • aspirin/dipyridamole (Aggrenox) • ticagrelor (Brilinta) • cilostazol (Pletal) • ticlopidine (Ticlid) • clopidogrel (Plavix) • tirofiban (Aggrastat) • dipyridamole (Persantine) • vorapaxar (Zontivity) • eptifibatide (Integrilin) Effective Date: 9/1/2021 TennCare Attestation List | Page 3 CARDIOVASCULAR Pulmonary Arterial Hypertension Agents • ambrisentan (Letairis) • riociguat (Adempas) • bosentan (Tracleer) • selexipag (Uptravi) • epoprostenol (Flolan) • sildenafil (Revatio) • iloprost (Ventavis) • tadalafil (Adcirca) • macitentan (Opsumit) • treprostinil (Remodulin, Tyvaso, Orenitram) Statins • simvastatin (Flolipid) Vasodilators • amyl nitrite • nitroglycerin (Minitran, Nitrek, Nitro-Bid, Nitro-Dur, • isosorbide dinitrate (Dilatrate-SR, Isochron, Isordil) Nitrolingual, NitroQuick, Nitrostat, Nitrotab, Nitro-Time, • isosorbide mononitrate (Imdur, Monoket) NitroMist) Vasopressors • midodrine CNS Alzheimer’s Agents • donepezil • memantine-donepezil • galantamine • rivastigmine • memantine Anticonvulsants • brivaracetam (Briviact) • lamotrigine ODT (Lamictal ODT) • cannabidiol (Epidiolex) • levetiracetam (Keppra, Keppra XR) • carbamazepine (Carbatrol, Tegretol, Tegretol XR) • methsuximide (Celontin) • clobazam (Onfi, Sympazan) • midazolam spray (Nayzilam) • clonazepam (Klonopin) • oxcarbazepine (Trileptal, Oxtellar XR) • clonazepam ODT (Klonopin Wafer) • perampanel (Fycompa) • diazepam rectal gel (Diastat) • phenobarbital • diazepam spray (Valtoco) • phenytoin (Dilantin, Dilantin Kapseals, Phenytek) • divalproex sodium (Depakote, Depakote ER, Depakote • pregabalin (Lyrica) Sprinkles) • primidone (Mysoline) • eslicarbazepine (Aptiom) • rufinamide (Banzel) • ethosuximide (Zarontin) • stiripentol (Diacomit) • ethotoin (Peganone) • tiagabine (Gabitril) • ezogabine (Potiga) • topiramate (Topamax, Trokendi XR, Qudexy XR) • felbamate (Felbatol) • valproate sodium (Depacon) • fosphenytoin (Cerebyx) • valproic acid (Depakene, Stavzor) • gabapentin (Neurontin) • vigabatrin (Sabril) • lacosamide (Vimpat) • zonisamide (Zonegran) • lamotrigine (Lamictal, Lamictal XR) • fenfluramine (Fintepla) Antidepressants, New Generation • bupropion (Wellbutrin, Wellbutrin SR, Wellbutrin XL, Forfivo XL) • nefazodone (Serzone) • maprotiline • trazodone (Oleptro) • mirtazapine (Remeron, Remeron SolTab) • vilazodone (Viibryd) Antidepressants, SNRIs, and SSRIs • (Celexa) • milnacipran (Savella) • desvenlafaxine (Pristiq, Khedezla) • (Paxil, Paxil CR, Pexeva) • duloxetine (Cymbalta, Irenka) • (Zoloft) • (Lexapro) • venlafaxine (Effexor XR) • (Prozac, Prozac Weekly, Sarafem) • vortioxetine (Trintellix) • (Luvox) Antiparkinson Agents • apomorphine (Apokyn, Kynmobi) • rasagiline (Azilect) • bromocriptine (Parlodel) • ropinirole (Requip, Requip XL) • carbidopa/levodopa (Sinemet, Sinemet CR, Rytary) • safinamide (Xadago) • carbidopa/levodopa/entacapone (Stalevo) • selegiline (Zelapar, Eldepryl) • entacapone (Comtan) • tolcapone (Tasmar) • pramipexole (Mirapex, Mirapex ER) • trihexyphenidyl (Artane) Effective Date: 9/1/2021 TennCare Attestation List | Page 4 CNS Antipsychotics, Atypical • aripiprazole (Abilify, Abilify Discmelt, Abilify Maintena, • lumateperone (Caplyta) Aristada) • lurasidone (Latuda) • asenapine (Saphris, Secuado) • olanzapine (Zyprexa, Zyprexa Zydis, Zyprexa Relprevv) • brexpiprazole (Rexulti) • paliperidone (Invega, Invega Sustenna, Invega Trinza) • cariprazine (Vraylar) • pimavanserin (Nuplazid) • clozapine (Clozaril, FazaClo) • quetiapine (Seroquel, Seroquel XR) • iloperidone (Fanapt) • risperidone (Risperdal, Risperdal
Load more

Recommended publications
  • Cefditoren Pivoxil) Tablets 200 and 400 Mg
    SPECTRACEF® (cefditoren pivoxil) Tablets 200 and 400 mg. To reduce the development of drug-resistant bacteria and maintain the effectiveness of SPECTRACEF® and other antibacterial drugs, SPECTRACEF® should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION SPECTRACEF® tablets contain cefditoren pivoxil, a semi-synthetic cephalosporin antibiotic for oral administration. It is a prodrug which is hydrolyzed by esterases during absorption, and the drug is distributed in the circulating blood as active cefditoren. Chemically, cefditoren pivoxil is (-)-(6R,7R)-2,2-dimethylpropionyloxymethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxy­ iminoacetamido]-3-[(Z)-2-(4-methylthiazol-5-yl)ethenyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate. The empirical formula is C25H28N6O7S3 and the molecular weight is 620.73. The structural formula of cefditoren pivoxil is shown below: cefditoren pivoxil The amorphous form of cefditoren pivoxil developed for clinical use is a light yellow powder. It is freely soluble in dilute hydrochloric acid and soluble at levels equal to 6.06 mg/mL in ethanol and <0.1 mg/mL in water. SPECTRACEF® (cefditoren pivoxil) tablets contain 200 mg or 400 mg of cefditoren as cefditoren pivoxil and the following inactive ingredients: croscarmellose sodium, D-mannitol, hydroxypropyl cellulose, hypromellose, magnesium stearate, sodium caseinate (a milk protein), and sodium tripolyphosphate. The tablet coating contains carnauba wax, hypromellose, polyethylene glycol, and titanium dioxide. Tablets are printed with ink containing D&C Red No. 27, FD&C Blue No. 1, propylene glycol, and shellac. CLINICAL PHARMACOLOGY Pharmacokinetics Absorption Oral Bioavailability Following oral administration, cefditoren pivoxil is absorbed from the gastrointestinal tract and hydrolyzed to cefditoren by esterases.
    [Show full text]
  • Medical Review(S) Clinical Review
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 200327 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number(s) 200327 Priority or Standard Standard Submit Date(s) December 29, 2009 Received Date(s) December 30, 2009 PDUFA Goal Date October 30, 2010 Division / Office Division of Anti-Infective and Ophthalmology Products Office of Antimicrobial Products Reviewer Name(s) Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD Review Completion October 29, 2010 Date Established Name Ceftaroline fosamil for injection (Proposed) Trade Name Teflaro Therapeutic Class Cephalosporin; ß-lactams Applicant Cerexa, Inc. Forest Laboratories, Inc. Formulation(s) 400 mg/vial and 600 mg/vial Intravenous Dosing Regimen 600 mg every 12 hours by IV infusion Indication(s) Acute Bacterial Skin and Skin Structure Infection (ABSSSI); Community-acquired Bacterial Pneumonia (CABP) Intended Population(s) Adults ≥ 18 years of age Template Version: March 6, 2009 Reference ID: 2857265 Clinical Review Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD NDA 200327: Teflaro (ceftaroline fosamil) Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ......................................... 9 1.1 Recommendation on Regulatory Action ........................................................... 10 1.2 Risk Benefit Assessment.................................................................................. 10 1.3 Recommendations for Postmarketing Risk Evaluation and Mitigation Strategies ........................................................................................................................
    [Show full text]
  • Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and Its Application
    Infect Dis Ther (2017) 6:57–67 DOI 10.1007/s40121-016-0144-8 REVIEW Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and its Application Juwon Yim . Leah M. Molloy . Jason G. Newland Received: November 10, 2016 / Published online: December 30, 2016 Ó The Author(s) 2016. This article is published with open access at Springerlink.com ABSTRACT infections, CABP caused by penicillin- and ceftriaxone-resistant S. pneumoniae and Ceftaroline is a novel cephalosporin recently resistant Gram-positive infections that fail approved in children for treatment of acute first-line antimicrobial agents. However, bacterial skin and soft tissue infections and limited data are available on tolerability in community-acquired bacterial pneumonia neonates and infants younger than 2 months (CABP) caused by methicillin-resistant of age, and on pharmacokinetic characteristics Staphylococcus aureus, Streptococcus pneumoniae in children with chronic medical conditions and other susceptible bacteria. With a favorable and those with invasive, complicated tolerability profile and efficacy proven in infections. In this review, the microbiological pediatric patients and excellent in vitro profile of ceftaroline, its mechanism of action, activity against resistant Gram-positive and and pharmacokinetic profile will be presented. Gram-negative bacteria, ceftaroline may serve Additionally, clinical evidence for use in as a therapeutic option for polymicrobial pediatric patients and proposed place in therapy is discussed. Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 1F47F0601BB3F2DD. Keywords: Antibiotic resistance; Ceftaroline J. Yim (&) fosamil; Children; Methicillin-resistant St. John Hospital and Medical Center, Detroit, MI, Staphylococcus aureus; Streptococcus pneumoniae USA e-mail: [email protected] L.
    [Show full text]
  • Empiric Antimicrobial Therapy for Diabetic Foot Infection
    Empiric Antimicrobial Therapy for Diabetic Foot Infection (NB Provincial Health Authorities Anti-Infective Stewardship Committee, September 2019) Infection Severity Preferred Empiric Regimens Alternative Regimens Comments Mild Wound less than 4 weeks duration:d Wound less than 4 weeks duration:e • Outpatient management • Cellulitis less than 2 cm and • cephalexin 500 – 1000 mg PO q6h*,a OR • clindamycin 300 – 450 mg PO q6h (only if recommended ,a • cefadroxil 500 – 1000 mg PO q12h* severe delayed reaction to a beta-lactam) without involvement of deeper • Tailor regimen based on culture tissues and susceptibility results and True immediate allergy to a beta-lactam at MRSA Suspected: • Non-limb threatening patient response risk of cross reactivity with cephalexin or • doxycycline 200 mg PO for 1 dose then • No signs of sepsis cefadroxil: 100 mg PO q12h OR • cefuroxime 500 mg PO q8–12h*,b • sulfamethoxazole+trimethoprim 800+160 mg to 1600+320 mg PO q12h*,f Wound greater than 4 weeks duration:d Wound greater than 4 weeks duratione • amoxicillin+clavulanate 875/125 mg PO and MRSA suspected: q12h*,c OR • doxycycline 200 mg PO for 1 dose then • cefuroxime 500 mg PO q8–12h*,b AND 100 mg PO q12h AND metroNIDAZOLE metroNIDAZOLE 500 mg PO q12h 500 mg PO q12h OR • sulfamethoxazole+trimethoprim 800+160 mg to 1600/320 mg PO q12h*,f AND metroNIDAZOLE 500 mg PO q12h Moderate Wound less than 4 weeks duration:d Wound less than 4 weeks duration:e • Initial management with • Cellulitis greater than 2 cm or • ceFAZolin 2 g IV q8h*,b OR • levoFLOXacin 750
    [Show full text]
  • In Silico Methods for Drug Repositioning and Drug-Drug Interaction Prediction
    In silico Methods for Drug Repositioning and Drug-Drug Interaction Prediction Pathima Nusrath Hameed ORCID: 0000-0002-8118-9823 Submitted in total fulfilment of the requirements for the degree of Doctor of Philosophy Department of Mechanical Engineering THE UNIVERSITY OF MELBOURNE May 2018 Copyright © 2018 Pathima Nusrath Hameed All rights reserved. No part of the publication may be reproduced in any form by print, photoprint, microfilm or any other means without written permission from the author. Abstract Drug repositioning and drug-drug interaction (DDI) prediction are two fundamental ap- plications having a large impact on drug development and clinical care. Drug reposi- tioning aims to identify new uses for existing drugs. Moreover, understanding harmful DDIs is essential to enhance the effects of clinical care. Exploring both therapeutic uses and adverse effects of drugs or a pair of drugs have significant benefits in pharmacology. The use of computational methods to support drug repositioning and DDI prediction en- able improvements in the speed of drug development compared to in vivo and in vitro methods. This thesis investigates the consequences of employing a representative training sam- ple in achieving better performance for DDI classification. The Positive-Unlabeled Learn- ing method introduced in this thesis aims to employ representative positives as well as reliable negatives to train the binary classifier for inferring potential DDIs. Moreover, it explores the importance of a finer-grained similarity metric to represent the pairwise drug similarities. Drug repositioning can be approached by new indication detection. In this study, Anatomical Therapeutic Chemical (ATC) classification is used as the primary source to determine the indications/therapeutic uses of drugs for drug repositioning.
    [Show full text]
  • Cross-Linking of Alpha 2-Plasmin Inhibitor to Fibrin by Fibrin- Stabilizing Factor
    Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin- stabilizing factor. Y Sakata, N Aoki J Clin Invest. 1980;65(2):290-297. https://doi.org/10.1172/JCI109671. Research Article The concentration of alpha 2-plasmin inhibitor in blood plasma is higher than that in serum obtained from the blood clotted in the presence of calcium ions, but is the same as that in serum obtained in the absence of calcium ions. Radiolabeled alpha2-plasmin inhibitor was covalently bound to fibrin only when calcium ions were present at the time of clotting of plasma or fibrinogen. Whereas, when batroxobin, a snake venom enzyme that lacks the ability to activate fibrin- stabilizing factor, was used for clotting fibrinogen, the binding was not observed. When fibrin-stablizing, factor-deficient plasma was clotted, the specific binding of alpha 2-plasmin inhibitor to fibrin did not occur even in the presence of calcium ions and the concentration of alpha 2-plasmin inhibitor in serum was the same as that in plasma. Monodansyl cadaverine, a fluorescent substrate of the fibrin-stablizing factor, was incorporated into alpha 2-plasmin inhibitor by activated fibrin-stablizing factor. All these findings indicate that alpha 2-plasmin inhibitor is cross-linked to fibrin by activated fibrin-stabilizing factor when blood is clotted. Analysis of alpha 2-plasmin inhibitor-incorporated fibrin by sodium dodecyl sulfate gel electrophoresis showed that the inhibitor was mainly cross-linked to polymerized alpha-chains of cross-linked fibrin. Cross-linking of alpha 2-plasmin inhibitor to fibrin renders fibrin clot less susceptible to fibrinolysis by plasmin.
    [Show full text]
  • Dopamine: a Role in the Pathogenesis and Treatment of Hypertension
    Journal of Human Hypertension (2000) 14, Suppl 1, S47–S50 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh Dopamine: a role in the pathogenesis and treatment of hypertension MB Murphy Department of Pharmacology and Therapeutics, National University of Ireland, Cork, Ireland The catecholamine dopamine (DA), activates two dis- (largely nausea and orthostasis) have precluded wide tinct classes of DA-specific receptors in the cardio- use of D2 agonists. In contrast, the D1 selective agonist vascular system and kidney—each capable of influenc- fenoldopam has been licensed for the parenteral treat- ing systemic blood pressure. D1 receptors on vascular ment of severe hypertension. Apart from inducing sys- smooth muscle cells mediate vasodilation, while on temic vasodilation it induces a diuresis and natriuresis, renal tubular cells they modulate sodium excretion. D2 enhanced renal blood flow, and a small increment in receptors on pre-synaptic nerve terminals influence nor- glomerular filtration rate. Evidence is emerging that adrenaline release and, consequently, heart rate and abnormalities in DA production, or in signal transduc- vascular resistance. Activation of both, by low dose DA tion of the D1 receptor in renal proximal tubules, may lowers blood pressure. While DA also binds to alpha- result in salt retention and high blood pressure in some and beta-adrenoceptors, selective agonists at both DA humans and in several animal models of hypertension. receptor classes have been studied in the treatment of
    [Show full text]
  • Therapeutic Class Overview Anticonvulsants
    Therapeutic Class Overview Anticonvulsants INTRODUCTION Epilepsy is a disease of the brain defined by any of the following (Fisher et al 2014): ○ At least 2 unprovoked (or reflex) seizures occurring > 24 hours apart; ○ 1 unprovoked (or reflex) seizure and a probability of further seizures similar to the general recurrence risk (at least 60%) after 2 unprovoked seizures, occurring over the next 10 years; ○ Diagnosis of an epilepsy syndrome. Types of seizures include generalized seizures, focal (partial) seizures, and status epilepticus (Centers for Disease Control and Prevention [CDC] 2018, Epilepsy Foundation 2016). ○ Generalized seizures affect both sides of the brain and include: . Tonic-clonic (grand mal): begin with stiffening of the limbs, followed by jerking of the limbs and face . Myoclonic: characterized by rapid, brief contractions of body muscles, usually on both sides of the body at the same time . Atonic: characterized by abrupt loss of muscle tone; they are also called drop attacks or akinetic seizures and can result in injury due to falls . Absence (petit mal): characterized by brief lapses of awareness, sometimes with staring, that begin and end abruptly; they are more common in children than adults and may be accompanied by brief myoclonic jerking of the eyelids or facial muscles, a loss of muscle tone, or automatisms. ○ Focal seizures are located in just 1 area of the brain and include: . Simple: affect a small part of the brain; can affect movement, sensations, and emotion, without a loss of consciousness . Complex: affect a larger area of the brain than simple focal seizures and the patient loses awareness; episodes typically begin with a blank stare, followed by chewing movements, picking at or fumbling with clothing, mumbling, and performing repeated unorganized movements or wandering; they may also be called “temporal lobe epilepsy” or “psychomotor epilepsy” .
    [Show full text]
  • Antibiotic Assay Medium No. 3 (Assay Broth) Is Used for Microbiological Assay of Antibiotics. M042
    HiMedia Laboratories Technical Data Antibiotic Assay Medium No. 3 (Assay Broth) is used for M042 microbiological assay of antibiotics. Antibiotic Assay Medium No. 3 (Assay Broth) is used for microbiological assay of antibiotics. Composition** Ingredients Gms / Litre Peptic digest of animal tissue (Peptone) 5.000 Beef extract 1.500 Yeast extract 1.500 Dextrose 1.000 Sodium chloride 3.500 Dipotassium phosphate 3.680 Potassium dihydrogen phosphate 1.320 Final pH ( at 25°C) 7.0±0.2 **Formula adjusted, standardized to suit performance parameters Directions Suspend 17.5 grams in 1000 ml distilled water. Heat if necessary to dissolve the medium completely. Sterilize by autoclaving at 15 lbs pressure (121°C) for 15 minutes. Advice:Recommended for the Microbiological assay of Amikacin, Bacitracin, Capreomycin, Chlortetracycline,Chloramphenicol,Cycloserine,Demeclocycline,Dihydrostreptomycin, Doxycycline, Gentamicin, Gramicidin, Kanamycin, Methacycline, Neomycin, Novobiocin, Oxytetracycline, Rolitetracycline, Streptomycin, Tetracycline, Tobramycin, Trolendomycin and Tylosin according to official methods . Principle And Interpretation Antibiotic Assay Medium is used in the performance of antibiotic assays. Grove and Randall have elucidated those antibiotic assays and media in their comprehensive treatise on antibiotic assays (1). Antibiotic Assay Medium No. 3 (Assay Broth) is used in the microbiological assay of different antibiotics in pharmaceutical and food products by the turbidimetric method. Ripperre et al reported that turbidimetric methods for determining the potency of antibiotics are inherently more accurate and more precise than agar diffusion procedures (2). Turbidimetric antibiotic assay is based on the change or inhibition of growth of a test microorganims in a liquid medium containing a uniform concentration of an antibiotic. After incubation of the test organism in the working dilutions of the antibiotics, the amount of growth is determined by measuring the light transmittance using spectrophotometer.
    [Show full text]
  • Pneumocystis Pneumonia and Disseminated
    1614 BRITISH MEDICAL JOURNAL VOLUmE 286 21 MAY 1983 Br Med J (Clin Res Ed): first published as 10.1136/bmj.286.6378.1614-a on 21 May 1983. Downloaded from Pneumocystis pneumonia and discussions, and Dr B Jameson and Dr D G Fleck for their valuable assistance disseminated toxoplasmosis in a with the pneumocystis and toxoplasma serology. Ammann A, Cowan M, Wara D, et al. Possible transfusion-associated male homosexual acquired immune deficiency syndrome (AIDS)-California. Morbidity and Mortality Weekly Report 1982;31 :652-4. 2 Du Bois RM, Branthwaite MA, Mikhail JR, et al. Primary pneumocystis Within the past two years 788 cases of the apparently new and carinii and cytomegalovirus infections. Lancet 1981 ;ii: 1339. potentially lethal syndrome of acquired immune deficiency have been Oswald GA, Theodossi A, Gazzard BG, et al. Attempted immune stimula- reported in the United States.' Only three cases have been reported in tion in the "gay compromise syndrome." Br MedJ' 1982;285:1082. the United Kingdom.2-4 We report a case in a previously healthy 37 4 Maurice PDL, Smith NP, Pinching AJ. Kaposi's sarcoma with benign course in a homosexual. Lancet 1982;i:571. year old male homosexual who was initially diagnosed and treated for Task force on acquired immune deficiency syndrome, Centers for Disease pneumocystis pneumonia and subsequently died of widespread Control. Update on acquired immune deficiency syndrome (AIDS)- toxoplasmosis. United States. Morbidity and Mortality Weekly Report 1982;31:507-14. (Accepted 4 March 1983) Case report The patient presented with an eight week history of malaise, non-produc- Departments of Microbiology and Medicine, St Thomas's Hospital, tive cough, night sweats, diarrhoea, anorexia, and weight loss.
    [Show full text]
  • Identification Ofa D1 Dopamine Receptor, Not Linked To
    Br. J. Pharmacol. (1991), 103, 1928-1934 11--" Macmillan Press Ltd, 1991 Identification of a D1 dopamine receptor, not linked to adenylate cyclase, on lactotroph cells 'Danny F. Schoors, *Georges P. Vauquelin, *Hilde De Vos, fGerda Smets, Brigitte Velkeniers, Luc Vanhaelst & Alain G. Dupont Department of Pharmacology, Medical School, Vrije Universiteit Brussel (V.U.B.), Laarbeeklaan 103, B-1090, Brussels, Belgium; *Protein Chemistry Laboratory, Instituut voor Moleculaire Biologie, V.U.B., Paardenstraat 65, St-Genesius-Rode, Belgium and tDepartment of Experimental Pathology, Medical School, V.U.B., Laarbeeklaan 103, B-1090, Brussels, Belgium 1 We studied the lactotroph cells of the rat by both in vivo and in vitro pharmacological techniques for the presence of D1-receptors. Both approaches revealed the presence of a D2-receptor, stimulated by quinpirole (resulting in an inhibition of prolactin secretion) and blocked by domperidone. 2 Administration of fenoldopam, the most selective Dl-receptor agonist currently available, resulted in a dose-dependent decrease of prolactin secretion in vivo (after pretreatment with a-methyl-p-tyrosine) and in vitro (cultured pituitary cells). This increase was dose-dependently blocked by the selective D1-receptor antagonist, SCH 23390, and although the effect of fenoldopam was less than that obtained by D2-receptor stimulation, these data suggest that a D,-receptor also controls prolactin secretion. 3 In order to detect the location of these dopamine receptors, autoradiographic studies were performed by use of [3H]-SCH 23390 and [3H]-spiperone as markers for D1- and D2-receptors, respectively. Specific binding sites for [3H]-SCH 23390 were demonstrated. Fenoldopam dose-dependently reduced [3H]-SCH 23390 binding, but had no effect on [3H]-spiperone binding.
    [Show full text]
  • Attachment: Product Information Brivaracetam
    Attachment 1: Product information for AusPAR AusPAR Briviact UCB Australia Pty Ltd PM- 2015-01568-1-1 Final 7 March 2017. This Product Information was approved at the time this AusPAR was published. PRODUCT INFORMATION BRIVIACT (brivaracetam) Solution for Injection NAME OF THE MEDICINE Non-proprietary name: Brivaracetam Chemical name: (2S)-2-[(4R)-2-oxo-4-propyltetrahydro-1H-pyrrol-1-yl]butanamide Chemical structure: Molecular formula: C11H20N2O2 MW: 212.29 CAS number: [357336-20-0] DESCRIPTION The active ingredient brivaracetam is a white to off-white crystalline powder. It is very soluble in water, buffer (pH 1.2, 4.5 and 7.4), ethanol, methanol, and glacial acetic acid. It is freely soluble in acetonitrile and acetone and soluble in toluene. It is very slightly soluble in n-hexane. BRIVIACT solution for injection contains the following excipients: sodium acetate trihydrate, glacial acetic acid, sodium chloride, water for injections. PHARMACOLOGY Mechanism of action Brivaracetam displays a high and selective affinity for synaptic vesicle protein 2A (SV2A) in the brain. Binding to SV2A is considered to be the primary mechanism for brivaracetam anticonvulsant activity, however, the precise mechanism by which brivaracetam exerts is anticonvulsant activity has not been fully elucidated. Effects on QT interval The effect of brivaracetam on QTc prolongation was evaluated in a randomized, double-blind, positive-controlled (moxifloxacin 400 mg)- and placebo-controlled parallel group study of brivaracetam (150 mg/day and 800 mg/day in two daily intakes) in 184 healthy subjects. There was no evidence that brivaracetam prolongs the QT interval. Seizure frequency Briviact Solution for injection PI g2016-263 Page 1 Attachment 1: Product information for AusPAR AusPAR Briviact UCB Australia Pty Ltd PM- 2015-01568-1-1 Final 7 March 2017.
    [Show full text]